CPC A61K 38/193 (2013.01) [A61K 47/68 (2017.08); A61P 7/00 (2018.01); A61K 38/00 (2013.01); C07K 14/47 (2013.01); C07K 14/53 (2013.01); C07K 19/00 (2013.01); C07K 2317/524 (2013.01); C07K 2317/53 (2013.01); C07K 2317/60 (2013.01); C07K 2319/30 (2013.01); C12N 15/62 (2013.01)] | 16 Claims |
1. A method of preventing neutropenia or reducing the duration of neutropenia of a subject in need thereof, wherein the subject has received or is received an anti-cancer chemotherapy, and wherein the method comprises administering a hybrid Fc fusion G-CSF of the following Formula (I) to the subject at a dose range between about 200 μg/kg and about 400 μg/kg administered 24 hours after the anti-cancer chemotherapy:
N′-G-Y-Z2-Z3-Z4-C′ Formula (I)
wherein
G is a G-CSF;
N′ is the N-terminal of a polypeptide and C′ is the C-terminal of a polypeptide;
Y is an amino acid sequence having 5 to 64 consecutive amino acid residues from the amino acid residue at position 162 toward the N-terminal, among the amino acid residues at positions from 99 to 162 of SEQ ID NO: 2;
Z2 is an amino acid sequence having 4 to 37 consecutive amino acid residues from the amino acid residue at position 163 toward the C-terminus, among the amino acid residues at positions from 163 to 199 of SEQ ID NO: 2;
Z3 is an amino acid sequence having 71 to 106 consecutive amino acid residues from the amino acid residue at position 220 toward the N-terminus, among the amino acid residues at positions from 115 to 220 of SEQ ID NO: 3; and
Z4 is an amino acid sequence having 80 to 107 consecutive amino acid residues from the amino acid residue at position 221 toward the C-terminus, among the amino acid residues at positions from 221 to 327 of SEQ ID NO: 3.
|